Oncotype DX-guided treatment could reduce cost for breast cancer care, study suggests
 

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the first year).

More...